Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
October 03 2023 - 6:36AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of October 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca settles Nexium liability litigations
3 October 2023
AstraZeneca
settles Nexium and Prilosec product liability
litigations
AstraZeneca has entered into settlement agreements in the product
liability litigations related to Nexium and Prilosec. The agreements effectively resolve the product
liability claims that are currently pending in the Multidistrict
Litigation in the US District Court for the District of New Jersey,
as well as in the Delaware Superior Court and the New Jersey
Superior Court. The specific terms of the agreements are
confidential.
AstraZeneca continues to believe these claims are without merit and
admits no wrongdoing in the settlement agreement. These settlements
avoid continued costly litigation and allow the Company to move
forward with its purpose of delivering life changing medicines to
millions of patients around the world.
A single case remains pending in the US District Court for the
Middle District of Louisiana. Trial is scheduled in that case for
April 15, 2024.
Financial considerations
AstraZeneca will make payment of $425 million, for which a
provision has been taken.
Notes
Nexium and Prilosec
Nexium and Prilosec are
prescription only drugs used to treat patients with acid-related
symptoms and diseases. Nexium and Prilosec can
provide relief for a range of patients, including those who are
frustrated by the disruption that the condition causes to their
life. Nexium and Prilosec work
by binding to and inhibiting the acid pumps of a particular type of
cells in the lining the stomach wall to stop the production of
stomach acid. In doing so, it lowers the level of acidity in the
stomach and helps to heal erosions in the esophagus or ulcers in
the stomach and duodenum. Both Nexium and Prilosec are
available via prescription to treat these diagnosable conditions
and over-the-counter in lower dosages to treat
heartburn.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
3 October 2023
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From May 2023 to May 2024